文献速递肿瘤 PET/CT

视觉评估18F-FDG PET摄取预测非小细胞肺癌PD-1阻断治疗生存获益

Visual Assessment of 18F-FDG Uptake on PET to Predict Survival Benefit to PD-1 Blockade in Non-Small Cell Lung Cancer.
PubMed 文献 · Clin Nucl Med · 2022-01-01

回顾性纳入38例晚期非小细胞肺癌患者,在确认PD-1阻断单药临床缓解后行18F-FDG PET,采用5分视觉评分法评估摄取,以3分为界分为低分(1-3分)和高分(4-5分)。低分患者无进展生存和总生存均显著长于高分患者,多变量分析证实低18F-FDG摄取是预测良好生存的独立预后因素。

要点

  • 38例中低分20例(53%)、高分18例(47%),低分者体能状态0或1分者显著更多。
  • 低分患者无进展生存和总生存均显著长于高分患者。
  • 多变量分析显示低18F-FDG摄取是良好无进展生存和总生存的独立预后因素。

核心结论

  • 18F-FDG摄取低于正常肝病灶的肿瘤可能对PD-1阻断治疗有更持久的缓解。
  • PET视觉评估简便,便于临床医生确认肿瘤活跃程度。

研究设计与样本

  • 回顾性纳入38例晚期非小细胞肺癌患者,均在确认对PD-1阻断单药临床缓解后行18F-FDG PET。
  • 采用5分视觉评分法评估18F-FDG摄取,以3分为界:低分定义为1、2或3分,高分定义为4或5分。

主要发现

  • 38例中低分20例(53%),高分18例(47%)。
  • 低分患者中体能状态0或1分者显著多于高分患者。
  • 低分患者无进展生存和总生存均显著长于高分患者。
  • 多变量分析证实低18F-FDG摄取是良好无进展生存和总生存的独立预后因素。

关键数值与推荐

  • 18F-FDG摄取5分视觉评分法中,低分为1、2或3分,高分为4或5分,界值为3分。

临床怎么用

  • 原文未据此给出推荐。
  • 作者认为,18F-FDG摄取低于正常肝病灶的肿瘤可能对PD-1阻断有更持久缓解,PET视觉评估简便易行。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Programmed death 1 (PD-1) blockade is a standard treatment for patients with metastatic non-small cell lung cancer (NSCLC). Approximately 20% patients receiving PD-1 blockade monotherapy can survive for more than 5 years. However, there are limited data on the optimal biomarkers for predicting long-term outcomes. Therefore, this study aimed to evaluate the prognostic significance of 18F-FDG uptake in patients with NSCLC responding to PD-1 blockade. PATIENTS AND METHODS: Thirty-eight patients with advanced NSCLC who underwent 18F-FDG PET after confirmation of clinical response to PD-1 blockade monotherapy were retrospectively included in this study. Visual assessment using a 5-point scale score according to 18F-FDG uptake was performed, and the 18F-FDG uptake cutoff score for prolonged response to PD-1 blockade was defined as 3 (low score: 1, 2, or 3 and high score: 4 or 5). RESULTS: A significantly greater number of patients with low scores had a performance status of 0 or 1 than patients with high scores. Among the 38 patients, 20 (53%) had a low score and 18 (47%) had a high score. Progression-free survival and overall survival were significantly longer in patients with low scores than in patients with high scores. Low 18F-FDG uptake was an independent prognostic factor for predicting favorable progression-free survival and overall survival, as confirmed by multivariate analysis. CONCLUSIONS: Tumors with lower 18F-FDG uptake on PET than normal hepatic lesions exhibit the possibility of prolonged response to PD-1 blockade. Visual assessment on PET is easy for every clinician and is understandable to confirm aggressive tumor activity.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Hashimoto K, Kaira K, Yamaguchi O, et al. Visual Assessment of 18F-FDG Uptake on PET to Predict Survival Benefit to PD-1 Blockade in Non-Small Cell Lung Cancer. Clin Nucl Med. 2022. PMID: 35006104. doi:10.1097/RLU.0000000000004009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。